Drug intelligence / Profile preview

ADX-743

Development stage: Preclinical
Lead developer: Aldeyra Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ADX-743 is an investigational, orally available small molecule developed by Aldeyra Therapeutics. It is a novel analog of ADX-629 and functions as an inhibitor of reactive aldehyde species (RASP). RASP are implicated in inflammatory and metabolic diseases, and inhibition may reduce inflammation and improve metabolic parameters. Preclinical studies have shown that ADX-743 lowers triglycerides and fatty acids, supporting its potential use in hypertriglyceridemia and obesity. The drug is currently in preclinical development for these indications[1][2][9][10].

Other names: ADX 743ADX743ADX-743

Beyond the preview

Go deeper on ADX-743.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADX-743.

Explore the full profile